tbuckley/cabot-search huggingface dataset:
Prévention des sténoses œsophagiennes cicatricielles après dissection sous muqueuse étendue, par greffe de double feuillet de cellules souches mésenchymateuses chez le porc
Authors: G Perrod, G Rahmi, L Pidial, S Camilleri, A Bellucci, T Viel, B Tavitian, C Cellier, O Clément
Journal: Endoscopy (2015)

La dissection sous muqueuse (DSM) des néoplasies superficielles étendues de l'œsophage est responsable de sténose cicatricielle. Le but de cette étude est d'évaluer l'impact de la greffe de cellules souches mésenchymateuses allogéniques (CSM) organisées en doubles feuillet comme traitement préventif de la survenue de ces sténoses chez le porc.
OP0225 Micrornas Underlie Plasmacytoid Dentritic Cell Dysfunction in Systemic Sclerosis
Authors: M. Rossato, J. C. Broen, N. P. Rossen, L. van Bon, T. R. Radstake
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs that carries a high burden of morbidity and mortality. Immune system dysfunction has been undisputedly demonstrated to underlie SSc pathogenesis. In particular, plasmacytoid dendritic cells (pDCs) not only circulate in very high number in SSc patients but also secrete high concentrations of specific chemokines that directly drive various features of SSc, including endothelial dysfunction and fibroblast activation. <h3>Objectives</h3> The aim of the study was to identify the molecular basis underlying pDC dysfunction and increased number in SSc patients. <h3>Methods</h3> pDCs were isolated from whole blood of early diffuse SSc, late diffuse SSc, limited SSc patients or healthy controls. The genome-wide profiling of microRNAs (miRNA) was performed on pDC total RNA by using the Illumina miRNA Profiling Array. Genes targeted by differentially expressed miRNAs were identified thanks to a combination of Miranda, Mirtar and MirPath prediction algorithms. <h3>Results</h3> miRNA screening demonstrated that seven miRNAs were significantly over- and two were under-expressed in pDCs from patients with early diffuse SSc compared to late diffuse disease, limited SSc or healthy controls and this profile perfectly correlated with pDC abundance in the different disease stages. According to Miranda, Mirtar and MirPath prediction algorithms, this set of 9 miRNAs is predicted to influence a vast number of target genes, mostly involved in three molecular pathways: 1) leukocyte apoptosis, 2) epidermal growth factor EGFR (ErbB) signaling and 3) WNT signaling. Interestingly, the emergence of the leukocyte apoptosis pathway might provide a preliminary hint on why pDCs are expanded early in SSc. On the other side, ErbB and WNT signaling are ultimately involved in immune response regulation and often linked to the malfunctioning of the immune system in SSc. <h3>Conclusions</h3> Altogether these unique observations suggest that SSc-associated miRNAs could strongly impact on cellular pathways involved in SSc pathology, and therefore they would provide an important target for disease prediction and therapeutic approaches. <h3>Acknowledgements</h3> This research was kindly supported by the ERC Starting European grant. <h3>Disclosure of Interest</h3> None Declared
ASSOCIATION BETWEEN DURATION OF ATRIAL FIBRILLATION AND ECHOCARDIOGRAPHIC MEASURES OF LEFT ATRIAL FUNCTION: INSIGHTS FROM THE ECHOCARDIOGRAPHIC SUBSTUDY OF THE AMIO-CAT TRIAL
Authors: Flemming Javier Olsen, Stine Darkner, Xu Chen, Steen Pehrson, Arne Johannessen, Jim Hansen, Jan Jensen, Jesper Hastrup Svendsen, Tor Biering-Sorensen
Journal: Journal of the American College of Cardiology (2016)
Endoscopic sclerotherapy with aluminum potassium sulfate and tannic acid for internal hemorrhoids
Authors: Yuichi Tomiki, Seigo Ono, Jun Aoki, Rina Takahashi, Kazuhiro Sakamoto
Journal: Endoscopy (2014)

Sclerotherapy with injection of aluminum potassium sulfate and tannic acid (ALTA) has been reported to be a new, valid treatment method for internal hemorrhoids that does not involve resection [1] [2]. With this method, ALTA is injected into the submucosa at the base of hemorrhoids by performing direct four-step injection (involving the upper, deep middle, shallow middle, and lower parts of the hemorrhoids) using an anoscope. We considered the possibility of using endoscopic injection instead of an anoscope in ALTA sclerotherapy.
SAT0523 The Usefulness of Procalcitonin for Differentiating Acute Gout Arthritis from Infectious Disease
Authors: J.S. Song, S.T. Choi, E.H. Park
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Acute gout arthritis is usually accompanied by tenderness, swelling, redness and fever. These features and laboratory findings including leukocytosis, elevation of serum ESR or CRP levels, are similar to those of infectious diseases. Moreover, normal to low serum uric acid levels have been noted in many cases of acute gout arthritis. For these reasons, the differential diagnosis of acute gout arthritis with infectious disease can be difficult. <h3>Objectives</h3> Procalcitonin, the precursor peptide of calcitonin, is known to be elevated in the patients with bacterial infection. We investigate whether or not serum procalcitonin levels are higher in patients with acute gout arthritis than in the others. We also evaluate the usefulness of procalcitonin for differentiating diagnosis between acute gout arthritis and bacterial infection. <h3>Methods</h3> The serum samples were obtained from 67 patients with acute gout arthritis and 90 age-matched patients with bacterial infection. Serum procalcitonin levels were measured by an enzyme-linked fluorescent assay. <h3>Results</h3> The serum procalcitonin levels in patients with acute gouty arthritis were significantly lower than those in patients with bacterial infection (0.096±0.105 ng/mL vs 4.941±13.763 ng/mL, <i>p</i> =0.001). However, other inflammatory parameters, such as ESR, CRP and WBC, showed no significant differences between these two groups. Patients with acute gout arthritis had statistically higher serum uric acid levels than the patients with bacterial infection (7.62±2.03 mg/dL vs 5.19±2.36 mg/dL, <i>p</i>&lt;0.001); however, 19.4% (13/67) among the acute gout arthritis group had lower uric acid level (below 6.0 mg/dL). To determine the discriminative ability of procalcitonin between acute gout arthritis and bacterial infection, we conducted ROC analysis about procalcitonin, uric acid, ESR, CRP and WBC. The area under the curve (AUC) of procalcitonin and uric acid were 0.852 (95% CI 0.793-0.911, <i>p</i>&lt;0.001) and 0.808 (95% CI 0.738-878, <i>p</i>&lt;0.001), respectively. There was no significance at ESR, CRP and WBC. With a cut off value of 0.095 ng/dL, the sum of sensitivity and specificity of procalcitonin were the highest (80.0% and 80.6%, respectively). <h3>Conclusions</h3> Serum procalcitonin levels were significantly lower in patient with acute gout arthritis than in patients with bacterial infection. The serum procalcitonin level is expected to be a useful serologic marker for the differentiating acute gout arthritis from bacterial infection. <h3>References</h3> Simon L et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004:39:206-17. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4127
BMI upon discharge from hospital and its relationship with survival: an observational study utilising linked patient records
Authors: Nick Freemantle, Daniel Ray, Milena Falcaro, David McNulty, Laura Shallcross, John Wood, Domenico Pagano
Journal: Journal of the Royal Society of Medicine (2016)

Current advice for patients being discharged from hospital suggests a body mass index of 18.5 to 24 kgm-2, although this aspirational target may often not be achieved. We examined the relationship between body mass index on discharge from hospital and subsequent mortality over a maximum follow-up of 3.8 years.We conducted a survival analysis using linked hospital records data with national hospital episode statistics and national death certification data.The analysis included adult patients who were admitted to University Hospitals Birmingham NHS Foundation Trust for a period of over 24 h during 2011, excluding day cases and regular day case attenders.The relationship between body mass index and mortality at medium term was estimated separately in both men and women, after accounting for case-mix.For both males and females, the relationship between body mass index at discharge and the loge hazard of death was strongly non-linear (p = 0.0002 for females and p < 0.0001 for males) and predictive (both p < 0.0001). In all models, the optimal body mass index range associated with best survival was 25 to 35 kgm-2, with a sharp increase in risk for lower body mass index.There was little evidence to support current aspirational body mass index targets in the discharge population. Hospitals should ensure adequate nutrition especially among those with a reduced body mass index.
Private finance, public risk
Authors: C. Ham
Journal: BMJ (1995)

Budget day brought an announcement of funding for the NHS in the coming year. More importantly, it also confirmed the British government's commitment to use private finance to pay for capital projects. After a slow start the private finance initiative seems to be gaining momentum across the public sector. In the case of the NHS, a number of major schemes are under development and private finance is increasingly replacing Treasury funding as the preferred method of raising money for new hospital developments. This is illustrated by projects in Norwich, Swindon, Leeds, Bishop Auckland, and Edinburgh, which are at an advanced stage of negotiation.

Government spokespeople cite these examples as evidence of the success of the private finance initiative and of the benefits that accrue from public-private partnerships. With pounds sterling2bn of private finance initiatives in the pipeline, including 25 schemes each to the value of pounds sterling25m or more, it would indeed seem that the initiative is beginning to bear fruit. Whereas originally …
Gastroscopie de dépistage à la méthode japonaise
Authors: H Kubo, T Tatagiba, B Napoléon, T Ponchon
Journal: Endoscopy (2007)

Si la fréquence du cancer de l'estomac est actuellement en baisse en France, il existe encore plus de 6000 nouveaux cas par an. Les cancers traités par voie endoscopique sont cependant exceptionnels. C'est une singularité du cancer de l'estomac puisque les mucosectomies œsophagiennes et duodénales sont en revanche courantes. Un des éléments limitant est certainement le pourcentage assez faible de lésions dépistées à un stade précoce et susceptibles d'être traitées de manière curative endoscopiquement. Ces données contrastent avec l'expérience japonaise où l'estomac est en première ligne des traitements endoscopiques avec le colon. L'incidence plus élevée de cancer au Japon et le dépistage systématique qui est organisé à l'échelle du pays, expliquent en partie ces différences. Il est probable également que l'œil endoscopique français est moins bien formé à la détection de ces petites tumeurs mais il n'est pas exclu que la technique même de la gastroscopie soit en cause. Objectif: Montrer un exemple de gastroscopie de dépistage réalisée par un expert japonais.
PWE-281 Different effector T cell responses may account for different patterns of liver injury in childhood autoimmune liver disease
Authors: R Liberal, C Grant, G Mieli-Vergani, D Vergani, M Longhi
Journal: Gut (2012)

<h3>Introduction</h3> Two childhood autoimmune liver diseases are recognised: “classical” autoimmune hepatitis (AIH) and AIH-sclerosing cholangitis overlap syndrome (also termed as autoimmune sclerosing cholangitis, ASC). ASC is characterised by ANA and/or SMA seropositivity, hypergammaglobulinaemia and interface hepatitis—all features typical of “classical” AIH—in conjunction with bile duct destruction. Previous studies showed that regulatory T-cells, a subset essential for immune-tolerance maintenance, are defective in both conditions. Whether different CD4 and CD8 effector T-cell responses account for the clinical spectrum of childhood autoimmune liver disease is unknown. Aims: to evaluate the frequency and phenotype of CD4 and CD8 T-cells in patients with AIH and ASC. <h3>Methods</h3> 6 patients with AIH, six patients with ASC, and six healthy subjects (HS) were studied. The frequency and phenotype of T-cells was evaluated by cytofluorimetry using monoclonal antibodies against CD3, CD4 and CD8. Expression of T-bet, RORC, IFN-g and IL-17 was determined by intracellular staining. <h3>Results</h3> The frequency of CD4<sup>pos</sup>cells within total lymphocytes was lower in ASC (36.5±3.6), compared to AIH (47.2±2.7, p=0.04) and HS (46.8±2.1, p=0.04). Conversely, ASC patients displayed higher percentage of CD8<sup>pos</sup>cells (31.8±2) than in AIH (21.8±2.5, p=0.01) and HS (22.9±1.3, p=0.03), therefore exhibiting a lower CD4:CD8 compared to AIH and HS. Within CD4<sup>pos</sup>T-cells: (a) T-bet<sup>pos</sup> and IFN-g<sup>pos</sup>cells were higher both in AIH and ASC compared to HS (T-bet: p=0.01 for AIH, p=0.05 for ASC; IFN-g: p=0.02 for AIH, p=0.03 for ASC); (b) RORC<sup>pos</sup> and IL-17<sup>pos</sup>cells were more frequent in ASC than in AIH (RORC: p=0.001; IL-17: p=0.02). Within CD8-T cells: (a) IFN-g-producing cells were higher in AIH and ASC than HS (p=0.004 for AIH, p=0.08 for ASC); b) IL-17-producing cells were higher in ASC compared to AIH (p=0.05). In ASC, frequency of CD4<sup>pos</sup> and CD8<sup>pos</sup>IL-17<sup>pos</sup>cells correlated with γ-glutamyl-transpeptidase (R=0.90, p=0.01 for CD4; R=0.84, p=0.04 for CD8), and with alkaline phosphatase levels (R=0.75, p=0.09 for CD4; R=0.80, p=0.06 for CD8). <h3>Conclusion</h3> Both AIH and ASC are associated with an increase of IFN-g-producing cells. Compared to AIH, ASC patients have more CD8 T-cells, and higher number of IL-17-producing T-cells. The correlation with cholestatic biochemical abnormalities suggests that IL-17 is involved in bile duct involvement characteristic of ASC. <h3>Competing interests</h3> None declared.
A phase I trial of ABI-007, nanoparticle paclitaxel, administered to patients with advanced non-hematologic malignancies
Authors: D. W. Nyman, K. J. Campbell, E. Hersh, K. Richardson, K. Patrick, V. Trieu, N. Desai, D. D. Von Hoff
Journal: Journal of Clinical Oncology (2004)

2027 Background: To evaluate the safety/tolerability, maximum tolerated dose (MTD), and anti-tumor effect of nanoparticle paclitaxel (ABI-007). This novel Cremophor-free formulation was administered intravenously during weekly monotherapy to patients with advanced non-hematologic malignancies. This single center, Phase I, open-label study also evaluated the pharmacokinetic profile of ABI-007. Methods: Thirty nine patients were enrolled and received doses of ABI-007 ranging from 80 mg/m2/day to 200 mg/m2/day as a 30 minute IV infusion once a week for 3 weeks followed by a week of rest. A standard “3+3” design was used for dose escalation. Patients were divided into 2 groups, those who had been heavily pre-treated (HP) with prior anti-neoplastic therapy and those who had not (LP). Results: Thirty-nine patients were treated with >169 courses (3 cycles/course) of ABI-007. There were no hypersensitivity reactions to this formulation. The DLT in this trial for HP patients was grade 4 neutropenia and grade 3 peripheral neuropathy for LP patients. The MTD for HP patients is 100 mg/m2. The MTD for LP patients is 150 mg/m2. Other toxicities reported included fatigue, nausea/vomiting, mild anemia, and alopecia. To date, 5 patients have had a partial response including one with lung cancer (4 mos.), one with breast cancer (7mos.), and three with ovarian cancer (13 mos., 10 mos., and 4 mos.). These patients all had prior therapy with paclitaxel. Over the dose range of 80–150 mg/m2, the range of mean values for plasma clearance was 22–31 L/hr/m2, the means for plasma half-life were 15–18 hr, and the means for apparent volume of distribution were 549–772 L/m2. Pharmacokinetic analyses of ABI-007 exhibited linear increases for Cmax and area under the curve (AUC). Conclusion: Our results indicate that ABI-007 can be given safely on a weekly schedule without premedication for possible anaphylaxis and with minimum toxic side effects. Antitumor activity has been documented in patients with lung, ovarian, and breast cancer, and in patients who have had prior taxane therapy. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration American BioSciences, Inc.
Treatment of bipolar disorder
Authors: Michael Barde, Frank Bellivier
Journal: American Journal of Psychiatry (1996)

Bipolar disorder is a chronic pathology whose management must lead to limit the social, professional and family impacts as well as suicidal risk. The treatment of acute episodes and prophylaxis is based on mood stabilizer treatments whose lithium is a leader. They will be chosen according to the background and history of the disease. Anti-depressants must be used with care to minimize the risk of manic episode and the induction of rapid cycles. The prognosis is not solving major episodes but avoiding major mood episodes. The management of residual symptoms (especially neuro-cognitive) is also a major challenge prognosis and justifies the implementation of adjuvant psychotherapeutic strategies.
Case 12-2010
Authors: Richard L. Kradin, Subba R. Digumarthy, Aaron L. Baggish, Eugene J. Mark
Journal: New England Journal of Medicine (2010)

An 89-year-old man was admitted to the hospital because of progressive dyspnea for 6 months, worsening over the past 3 days. He had a history of exposure to asbestos and had smoked cigarettes for many years. Imaging studies revealed a pleural plaque and pulmonary interstitial fibrosis with superimposed ground-glass opacities. Hypoxemia and intermittent hypotension occurred. Despite oxygen supplementation, mechanical ventilation, and pressor administration, a cardiac arrest occurred, and the patient died on the eighth hospital day. An autopsy was performed.
P1316 EFFICACY AND FEASIBILITY OF A FIXED MONTHLY SCHEDULE OF SUBCUTANEOUS (SC) HUMAN HBV-IMMUNOGLOBULINS (HBIG) TO PREVENT HBV RECURRENCE AFTER LIVER TRANSPLANTATION. AN ITALIAN SINGLE-CENTRE EXPERIENCE
Authors: R. Volpes, L. Galatioto, G. Vizzini, B. Gridelli
Journal: Journal of Hepatology (2014)
Abstract 3649: Expression of CXCR5 and its natural ligand CXCL13 in ovarian cancer
Authors: Rajesh Singh, William E. Grizzle, Shailesh Singh, James W. Lillard
Journal: Cancer Research (2012)

Abstract Ovarian carcinoma (OvCa) is the most lethal gynecological malignancy among women and its poor prognosis is mainly due to metastasis. Chemokines and their corresponding receptors play an important role in metastasis and organ specific homing of cancer cells including OvCa. CXCL13 is a homeostatic chemokine for lymphocyte- and prostate cancer cell-homing and -positioning within secondary lymphoid tissues. This important chemokine acts through its only known receptor, CXCR5. In this study, we provide the first evidence that in OvCa CXCR5 and CXCL13 are highly elevated in OvCa cell lines and clinical samples. Flow cytometry analysis of OvCa cell lines (OVCAR-3 and SK-OV-3) show significantly higher expression of CXCR5 in comparison to normal adult ovarian epithelial cells. To determine the clinical significance of CXCR5 expressed by OvCa cell lines, ovarian cancer tissue microarrays were stained for CXCR5 and CXCL13. Aperio ScanScope scanning system was used to quantify the immuno-histochemical staining of CXCR5 and CXCL13. Our results show significantly higher expression of CXCR5 and CXCL13 (p &amp;lt; 0.001) in cancerous tissue than compared to non-neoplastic ovarian tissue. Among cancerous tissues, CXCR5 and CXCL13 expression was highest in serous adenocarcinoma followed by serous papillary cystadenoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, cystadenoma, mucinous boderline adenocarcinoma, clear cell carcinoma, granulosa cell tumor, dysgerminoma, transitional cell carcinoma, brenner tumor, yolk sac tumor, adenocarcinoma and fibroma. These data demonstrate biological and clinical significance of CXCR5 and CXCL13 as an OvCa biomarker. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3649. doi:1538-7445.AM2012-3649
Abstract 2157: A novel role for Giα proteins in differentially regulating activation of RTK-mediated signaling
Authors: Wen-Ming Chu, Zhanwei Wang, Rica Dela cruz, Catherine Chu, Jianhua Zhang, Meisheng Jiang
Journal: Cancer Research (2012)

Abstract The activation of the extracellular-signal-regulated protein kinase (ERK) pathway and the PI3K/Akt/mTORC pathway by growth factors is mediated by the receptor tyrosine kinases (RTKs), and plays a crucial role in physiological and pathological processes including cell proliferation, growth, survival, migration, tumorigenesis and metastasis. We previously reported that the activation of the PI3K/Akt/mTORC1 in mouse embryonic fibroblasts (MEFs) by epidermal growth factor (EGF) and its family growth factors is mediated by the heterotrimeric G protein alpha inhibitory (Giα). Herein we demonstrated that Giα proteins are able to differentially regulate RTKs-mediated activation of the ERK and the Akt/mTORC1 pathways. Loss of Giα proteins in MEFs impaired activation of the ERK pathway by EGF, insulin-like growth factor (IGF) and Insulin, but not basic fibroblast growth factor (bFGF). Intriguingly, while activation of the Akt/mTORC1 pathway by EGF and bFGF was severely defective in Giα protein deficient cells, this activation was only slightly reduced in response to insulin and IGF. Also, Giα proteins were able to alter activation of the Akt/mTORC1 and the ERK pathways by serum and platelet-derived growth factor (PDGF) in a dose dependent manner. To further understand that how Giα proteins differentially regulate RTK-mediated activation of the Akt/mTORC1 and ERK pathways, we performed an immuno-precipitation study. Our results showed that growth factors were able to induce the association of Giα proteins with growth factor receptors and their downstream adaptor proteins. Loss of Giα proteins in MEFs impaired the association of growth factor receptors with their adaptor proteins indicating that Giα proteins act downstream of RTKs but upstream of the adaptor proteins. Finally, we examined a role of Giα proteins in cancer biology. Similar to results obtained from Giα deficient MEFs, knockdown of Giα proteins in several human cancer cell lines diminished activation of the Akt/mTORC1 and the ERK pathways by growth factors. As a result, Giα protein deficiency inhibited cancer cell growth and migration. Given the fact that growth factors and their receptor pathways play pivotal roles in tumorigenesis and metastasis of cancer, our findings may promote further understanding the molecular mechanism underline RTK signaling regulation in cancer biology and may have implications for cancer therapy. Supported by Department of Defense, Leukemia and Lymphoma Society and NIH. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2157. doi:1538-7445.AM2012-2157